Data from BioTime’s OpRegen® and Retinal Restoration Programs to Be Presented at ARVO 2018

ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that data from the ongoing OpRegen® clinical trial and Retinal Restoration program will be presented at the upcoming Association for Research in Vision and Ophthalmology (ARVO) meeting taking place from April 29th – May 3rd, 2018, in Honolulu, Hawaii. The scheduled times (noted in local Hawaii time) and location of the BioTime data presen

Full Story →